The Budget Impact of Introducing Ranibizumab in England and Wales for the Treatment of Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Abstract

A503(vPDT) fell from 93% to 68%. In the 'without ranibizumab' scenario, only vPDT was administered. Costs of treatment, administration, monitoring, bilateral disease and management of recurrences were included. Results: An estimated 2045 patients were eligible for treatment at year 1 and 2119 at year 5. In the 'with ranibizumab' scenario, 143 patients received ranibizumab at year 1, increasing to 678 at year 5; 1902 patients received vPDT at year 1 and 1441 at year 5. 'With ranibizumab' annual costs were higher in years 1-2 than 'without ranibizumab' costs. During years 3, 4 and 5, cost savings occurred with ranibizumab (£3867, £121 584 and £232 467, respectively), owing to lower total costs of treatment and monitoring than with vPDT. The total 5-year saving 'with ranibizumab' over 'without ranibizumab' was £227 086. ConClusions: Treating visual impairment due to CNV secondary to PM with ranibizumab rather than vPDT is estimated to provide significant cost savings in England and Wales over 5 years.